Brilinta vs Leqvio
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Brilinta | US Leqvio | |
|---|---|---|
| Generic name | ticagrelor | inclisiran |
| Drug class | P2Y12 Platelet Inhibitor (Antiplatelet) | siRNA PCSK9-Lowering Therapy |
| Treats | Acute coronary syndrome, heart attack prevention | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | AstraZeneca | Novartis |
| Year approved | 2011 | 2021 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $120M | $90M |
| Common side effects | Bleeding, Shortness of breath, Bruising, Headache | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath |
Frequently asked questions
Is Brilinta or Leqvio better?
Neither is universally "better." Brilinta (ticagrelor) and Leqvio (inclisiran) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Brilinta and Leqvio?
Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca, while Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Brilinta has the larger estimated TV advertising budget of the two.